Clonazepam

Used alone or with other antiseizure medicines for Lennox-Gastaut syndrome, akinetic seizures, and myoclonic seizures. It may help absence seizures that have not responded to succinimides. Anticonvulsant effectiveness can diminish during continued treatment.

Labeled for panic disorder with or without agoraphobia. Safety and effectiveness below age 18 years have not been established. Controlled efficacy trials lasted 6–9 weeks; continued treatment requires periodic reassessment. The reviewed label does not establish treatment of every anxiety disorder.

These selected tablet and ODT labels use the same indication-specific regimens. Higher panic doses were less effective and caused more adverse effects than 1 mg/day in the fixed-dose trial; the maximum is not a routine target.

Follow the label’s stated age/weight population and a specialist plan; do not extrapolate it to pediatric panic disorder. Divide the daily dose into three equal doses when possible; if unequal, give the largest dose at bedtime. Long-term developmental benefit and risk require reassessment.

Swallow Klonopin tablets whole with water. For the selected ODT, peel the blister foil back; do not push the tablet through it. With dry hands, immediately place the tablet in the mouth and let it disintegrate in saliva; swallow with or without water. This is an oral disintegrating product, not an approved sublingual rescue formulation.

Use an individualized gradual taper; higher doses and longer exposure increase withdrawal risk. If withdrawal develops, the prescriber may pause the taper or return to the previous tapered dose, then reduce more slowly. The panic section describes reducing each twice-daily dose by 0.125 mg every 3 days, but that example is not a universal taper for established dependence. Start older patients low and monitor closely. The label supplies no validated numeric renal adjustment; significant liver disease is contraindicated.

A history of benzodiazepine sensitivity, clinical or biochemical evidence of significant liver disease, and acute narrow-angle glaucoma. The label permits use in appropriately treated open-angle glaucoma.

Both reviewed products carry boxed warnings for concomitant opioids; abuse, misuse, and addiction; and physical dependence and withdrawal. Reserve opioid combinations for inadequate alternatives, use the lowest effective doses and minimum durations, and monitor respiration and sedation. Gradually taper when reducing or stopping regular treatment.

Drowsiness, impaired coordination or ataxia, dizziness, fatigue, and memory problems are prominent. Depression and behavioral changes are reported. Respiratory depression and blood-count or liver-test abnormalities can occur. Trial frequencies differ between seizure and panic populations and should not be treated as universal rates.

Opioids, alcohol, hypnotics, other benzodiazepines, sedating antipsychotics or antidepressants, and other anticonvulsants can intensify CNS depression. Avoid alcohol; opioid combinations need the boxed-warning precautions and close monitoring.

Enzyme-inducing antiseizure drugs can lower clonazepam concentrations. CYP3A inhibitors, including azole antifungals, may increase effects; use caution when starting or stopping interacting drugs. Klonopin advises phenytoin concentration monitoring because clonazepam may influence it; the selected ODT label states that an effect was not apparent. Retain clinical and level monitoring rather than assume absence of interaction. Valproic acid with clonazepam may provoke absence status.

Published observational benzodiazepine data do not show a clear association with major birth defects, but uncertainty and animal developmental toxicity remain. Late-pregnancy exposure can cause neonatal sedation, respiratory depression, feeding problems, or withdrawal; arrange monitoring. Offer the NAAED Pregnancy Registry. Clonazepam enters milk: weigh maternal need and breastfeeding benefits, and monitor the infant for sedation, poor feeding, or poor weight gain.

Pediatric seizure treatment requires long-term developmental benefit-risk assessment. Pediatric panic safety and efficacy are unestablished below 18 years. Trials in patients aged 65 years or older are limited; start low, reassess sedation and confusion, and consider hepatic and renal function.

Renal and hepatic disease effects on PK have not been formally studied. Renal elimination of metabolites warrants caution in impaired kidney function. Hepatic metabolism may be reduced in liver disease, and significant liver disease is contraindicated. COPD, sleep apnea, and difficulty managing secretions increase the need for careful assessment.

The selected Advagen ODT contains aspartame and 0.56 mg phenylalanine per tablet at each listed strength. Klonopin tablets contain lactose and strength-specific colorants. Check the exact formulation when excipients matter.

The precise antiseizure and antipanic mechanism is uncertain; enhancement of GABA’s inhibitory CNS activity is believed to contribute.

CYP3A participates in metabolism. Protein binding is approximately 85%. A long half-life does not eliminate interdose symptoms or withdrawal risk, and organ-impairment PK remains incompletely characterized.

Oral bioavailability

About 90%

Peak concentration

Approximately 1–4 hours

Elimination half-life

Usually 30–40 hours

Disposition

Extensive metabolism; <2% excreted unchanged in urine

Assess seizure frequency or panic response, sedation, coordination, cognition, respiratory status, mood, and misuse risk. Reassess continued benefit and emerging tolerance; periodically check blood counts and liver function during long-term treatment as the label advises. Monitor phenytoin levels when coadministered and organ function when clinically indicated.

• Take only the prescribed dose; do not share this Schedule IV medicine. Store it securely.
• Avoid alcohol and check before adding opioids, sleep medicines, or other sedatives. Avoid driving or hazardous work until effects are known.
• Do not abruptly stop or rapidly reduce regular treatment. Contact the prescriber for withdrawal symptoms, worsening seizures, mood changes, or paradoxical behavior.
• Read the Medication Guide at each dispensing; discuss pregnancy or breastfeeding and infant monitoring.

Severe sleepiness, inability to awaken, slowed breathing, or collapse needs emergency care. Overdose management supports airway and circulation; flumazenil can trigger withdrawal seizures, particularly with epilepsy, dependence, or mixed overdose, and is not a home antidote. U.S. Poison Control: 1-800-222-1222; call 911 for impaired breathing or inability to awaken.

The 1 mg product is blue and the 2 mg product white; both are unscored with K-shaped perforations and strength-specific KLONOPIN imprints. These details apply to the selected brand.

Strength / form

0.5 mg oral tablet

Appearance

Orange; scored; K-shaped perforation

Imprint

1/2 KLONOPIN on front; reverse scored without imprint

Package example

H2-Pharma bottle of 100 · NDC 61269-605-10

Reviewed Klonopin tablets: 0.5, 1, and 2 mg. Reviewed Advagen ODT: 0.125, 0.25, 0.5, 1, and 2 mg; white round tablets with strength-specific B1–B5 imprints. These ODTs have different excipients and handling instructions. Other manufacturers and compounded liquids require their own verification.

Store both reviewed products at 25°C (77°F), with permitted excursions to 15–30°C (59–86°F). Keep ODTs in their blisters until use and handle with dry hands. Keep secure and away from children; use the exact product’s dispensing and disposal instructions.